

MEDX HOLDINGS, INC.
A WYOMING CORPORATION

COMPANY INFORMATION AND DISCLOSURE STATEMENT

Pursuant to Pink Sheet Basic Disclosure Guidelines

All information in this Information a Disclosure Statement has been compiled to fulfill the disclosure requirement of the OTC Markets regarding Pink Sheet Basic Disclosure Guidelines.

No Dealer, salesman or any other person has been authorized to give any information, or to make any representation, not contained herein in connection with the issuer. Such information or representations if made should not be relied upon as having been authorized by the issuer and;

Delivery of this information file does not at any time imply that the information contained herein is correct as of any time subsequent to the date first written

The undersigned hereby certifies that the information herein is true and correct to the best of their knowledge and belief.

Date: August 11, 2016

MedX Holdings, Inc.

/s/ Kathleen Robertson

Name: Kathleen Robertson

Position: Director & CEO

kathy@medxholdings.com

MEDX HOLDINGS, INC.

DISCLOSURE STATEMENT

Item 1: The exact name of the Issuer and the address of its executive offices:

The exact name of the issuer is: MedX Holdings, Inc.

August 12, 2015 – Cantor Group, Inc.

November 13, 2006 – Disaboom Inc.

September 5, 2006 – Disaboo, Inc.

Item 2: The Address of its principal executive offices:

1621 Central Avenue
Cheyenne, WY 82001

Phone: 877-225-0243
Fax: 954-337-3756

Item 3: Security Information

Security Symbol:	MEDH
CUSIP Number:	58403T 107
Common Stock	25,569,016
Par Value:	\$0.001 on both Common and Blank Check Preferred

Authorized Share Structure: As of 6/30/2016

Common Stock: 100,000,000

Blank Check Preferred: 100,000,000

Transfer Agent:

Daniel Bell, Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
Denver, Colorado 80209
Phone: 303-282-4800

CST currently meets all requirements and is registered under the Securities Exchange Act.

Restriction on transfer of Securities or suspensions by the SEC in the past 3 months:

NONE

Item 4: Issuance History

For the period ending June 30, 2016 One Hundred Thousand shares of Series A Preferred shares were issued per \$50,000 dollars invested.

Item 5: Financial Statements:

- Balance Sheet
- Statement of Income
- Statement of Cash flows
- Financial Notes

MEDX HOLDINGS, INC.
(A Development Stage Company)
Balance Sheet
As of June 31, 2016

	Total	
	As of June 30, 2016	As of Dec 31, 2015
ASSETS		
Current Assets		
Cash	\$ 32,705	\$ 1,709
Note Receivable MEDX Pharmaceuticals	12,133	
Total Current Assets	44,838	1,709
Other Assets		
CAPITAL ASSETS	146,000	146,000
Capitalized Re-Organization Costs	13,000	13,000
Intellectual Property	200	
Total Other Assets	159,200	159,000
TOTAL ASSETS	204,038	160,709
LIABILITIES AND EQUITY		
Liabilities		
Current Liabilities		
Accrued Interest	338	
Accrued Salary	45,000	-
Due to related party	29,293	27,000
Total Current Liabilities	74,631	27,000
Long Term Liabilities		
Convertible Notes	11,000	
Total Long Term Liabilities	11,000	
Total Liabilities	85,631	27,000
Equity		
Common Stock	4,221	4,221
Paid-In Capital or Surplus	717,239	717,239
Preferred Stock Series "A"	50,000	
Retained Earnings	(587,751)	(587,460)
Net Income	(65,302)	(291)
Total Equity	118,408	133,709
TOTAL LIABILITIES AND EQUITY	\$ 204,038	\$ 160,709

The accompanying notes are an integral part of these financial statements.

MEDX HOLDINGS, INC.
(A Developing Stage Company)
Profit and Loss

April - June 2016, January - June 2016 & January - December 2015

	April - June 2016	January - June 2016	Jan - Dec 2015	Cumulative results from September 6, 2006 (Inception date) to June 30, 2016
Income				
Total Income				
Expenses				
Professional Fees	\$ 8,500	\$ 9,300		\$ 35,724
Office/General Administrative Expenses	2,917	2,960	291	8,201
FINRA Compliance	991	5,416		9,841
Payroll Expense	45,000	45,000		45,000
Interest Expense	338	338		338
Legal	80	1,204		1,204
Travel	315	1,084		1,853
Prior period other expense				554,892
Total Expenses	58,141	65,302	291	657,053
Net Loss	\$ (58,141)	\$ (65,302)	\$ (291)	\$ (657,053)

STATEMENT OF STOCKHOLDERS' DEFICIT

BASIC LOSS PER COMMON SHARE	0.00	0.00
FULLY DILUTED LOSS PER COMMON SHARE	0.00	0.00
Weighted Average number of Common Shares Outstanding	25,569,016	25,369,016
Fully diluted weighted average number of Shares Outstanding	73,805,683	65,369,016

The accompanying notes are an integral part of these financial statements.

MEDX HOLDINGS, INC
(A Development Stage Company)
Statement of Cash Flows

April - June 2016 January - June 2016 January - December 2015

	April-June 2016	January - June 2016	January - December 2015	Cumulative results from September 6 2006 (inception date) to June 30, 2016
OPERATING ACTIVITIES				
Net Loss	\$ (58,140)	\$ (65,302)	\$ (291)	(657,053)
Adjustments to reconcile Net Income to Net Cash provided by operations:				
Note Receivable MEDX Pharmaceuticals	(12,133)	(12,133)		(12,133)
Accrued Liabilities	45,338	45,338	(16,000)	45,338
Due to related party	2,365	2,293	27,000	29,293
Net cash provided by operating activities	(22,571)	(29,804)	10,709	(594,555)
INVESTING ACTIVITIES				
Acquire Intellectual Property (LOGO)		(200)		(200)
Capitalized Re-Organization Costs			(13,000)	(13,000)
Purchase of Capital Asset				(146,000)
Net cash provided by investing activities	-	(200)	(13,000)	(159,200)
FINANCING ACTIVITIES				
Increase in Long Term liability (Convertible Notes)		11,000		11,000
Common Stock			-	4,221
Paid-In Capital				717,239
Preferred Stock Series "A"	50,000	50,000		50,000
Retained Earnings			4,000	4,000
Net cash provided by financing activities	50,000	61,000	4,000	786,460
Net cash increase for period	27,429	30,996	1,709	32,705
Cash at beginning of period	5,276	1,709		-
Cash at end of period	\$ 32,705	\$ 32,705	\$ 1,709	\$ 32,705

The accompanying notes are an integral part of these financial statements

MEDX HOLDINGS, INC.
(A Development Stage Company)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
JUNE 30, 2016

NOTE 1 - SUMMARY OF OPERATIONS AND BASIS OF PRESENTATION

MedX Holdings, Inc. formerly Cantor Group Inc. (the "Company") was incorporated in the State of Wyoming on December 23, 2015. The company has an established fiscal year end of December 31.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America and are presented in US dollars.

Cash and Cash Equivalents

The company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Financial Instruments

The carrying value of the company's financial instruments approximates their fair value because of the short maturity of these instruments.

Basic and Diluted Net Loss per Share

The Company computes loss per share in accordance with "ASC-200". "Earnings per Share" which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Dilutive loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. The Company has issued four notes (DUE RELATED PARTIES) which are potential dilutive instruments and accordingly, basic loss and diluted loss per share are presented.

In February of 2016 the company borrowed \$ 11,000 at 8% with conversion feature at 50% of bid of the previous 10-day average. The potential dilutive effect of these instruments is 146,667 shares.

During June of 2016 the company had two investments of \$ 25,000.00 each. These investors each received 50,000 shares of series "A" Preferred Stock, par value \$ 0.001 with conversion of 1 to 1. The dilutive effect of these transaction is an additional 100,000 shares of common.

The Basic Common Stock authorized is 100,000,000 shares. As of 06/30/2016 the number of issued shares is 25,569,016 outstanding. The weighted average of fully diluted shares is 73,805,683.

NOTE 3 – GOING CONCERN

The Company's financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has restructured its board and its management team and has raised equity capital to position the company as a holding company focused on acquisition and development of businesses primarily in the medical products industry. The Company is utilizing a new form of collaborative governance to create added value.

The company has entered the pharmaceutical distribution business with the creation of MEDX PHARMACEUTICALS, INC., a wholly owned subsidiary. As of June 30, 2016 MEDX HOLDINGS, INC. has advanced \$ 12,133.00 as startup capital to begin operations.

The ability of the Company to continue as a going concern is dependent upon its continued ability to successfully accomplish the plans described in the preceding paragraphs. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

NOTE 4 - RELATED PARTY TRANSACTION

As of March 31, 2016 the Company owed \$ 12,000.00 in a Convertible Note with four (4) individuals each owning $\frac{1}{4}$ each of the note via a partial Note Assignment. The notes remain non-interest bearing. The notes convert at \$0.0001 up to 48,000,000 common Shares.

On November 17, 2015, Small Cap Pro LLC, funded a special purpose account on behalf of MEDX HOLDINGS, INC. in the amount of \$ 15,000.00 with the sole purpose of providing working capital to re-structure the operations, move the state of domicile from Colorado to Wyoming, and to establish corporate operations in order to implement the current strategic business plan. This note carries a statutory interest rate, is unsecured and is due on demand. As of 12/31/2015 the un-used amount in the SPE account was \$ 1709.25. The board of directors authorized that the claim of \$ 1709.25 towards Medx Holdings Inc. be released and the account be returned to its beneficial owner, Small Cap Pro LLC. Small Cap Pro LLC is wholly owned by the principle shareholder of MedX Holdings, Inc.

NOTE 5 – CAPITAL STOCK

As of June 30, 2016 the Company has:

Authorized Common Shares	100,000,000 Par Value \$0.001
Authorized to Issue Series A Preferred	3,000,000 Par Value \$0.001
Authorized Blank Check Preferred	97,000,000 Par Value \$0.001
Issued and outstanding:	25,569,016

NOTE 6 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were available to be issued and has determined that there are no significant events that need to be disclosed.

Item 6: Issuers Business, Products and Services:

MEDH specializes in providing privately held companies a platform where they can leverage the power of a public company while remaining in control of their private company. Our wholly-owned subsidiary, MedX Pharmaceuticals specializes in wholesale distribution of Generic RX drugs and is a manufacture using their own formulations for both RX and OTC drugs. MEDH acquired MedX Pharmaceuticals on June 10th, 2016.

MedX Pharmaceuticals, Inc. was incorporated in the state of Alabama on June 10th 2016 and was licensed as a Manufacture, Wholesaler and Repackager of Pharmaceuticals on June 29th 2016. The first product that MedX will sell will be 5% Lidocaine Ointment which is an RX product manufactured by a FDA Approved Manufacture for Finished Dosed Drugs. Plans are in place to expand our product line into the OTC Markets with three products MedX will manufacture. Our market includes licensed wholesale pharmacies, retail pharmacies, compounding pharmacies, licensed physicians and chiropractors.

MedX Pharmaceuticals, Inc. is located at 750 Lakeside Drive, Mobile Alabama 36693 and also has a Sales Office at 1500 W. Cypress Creek Road, Fort Lauderdale, FL 33309.

Item 7: Issuer's Facilities:

750 Lakeside Drive, Suite A Mobile, Alabama is just under 5,000 square feet. Approximately 3,500 sq. ft. are temperature controlled and serve as our offices and approved Drug Room. Close to 1,500 sq. ft. is a warehouse which will allow MedX to expand to include a FDA approved Clean Room.

MedX Pharmaceuticals, Inc. has a 5 Year Lease with the option to renew. This lease allows for both a early exit as well as purchase of the property. MedX base rent is \$2,440 per month.

1500 W. Cypress Creek Road Suite 302, Fort Lauderdale, FL 33309 is MedX Pharmaceutical's dedicated Sales Office. The office is approximated 1,000 sq. ft.

MedX Pharmaceuticals, Inc. has a 3 Year Lease with the option to renew. This lease allows for an early exit with no purchase option. MedX base rent is \$1,590 per month.

Item 8: Officer, Director and Control Persons:

Kathleen Robertson, Director & CEO

Percentage: Greater than 98%

Item 9: Third Party Providers

Legal Counsel:

Lorin A. Rosen, Esq.
Managing Attorney
Lar Law Firm
6 Butler Court
Centereach NY 11720

Accountant:

Irick CPA
Box 732
Counselor, NM 87018

Subsequent Events:

On July 26, 2015 there were two hundred and fifty thousand (250,000) shares issued of Series A Preferred Stock, par value \$0.001 and \$0.50 PPS. Fifty Thousand were issued for Services Rendered and two hundred thousand were issued subsequent to \$100,000 invested. Series A Preferred Stock converts 1 to 1 and are dividend earning.

Item 10: Issuers Certification

I Kathleen Robertson certify that:

1. I have reviewed this Quarterly report and;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference to this disclosure statement, fairly present in all material respects the financial conditions, results operations and cash flows of the issuer as of, and for, the period presented in this disclosure.

/s/ Kathleen Robertson, CEO

Kathleen Robertson, CEO